Faculty Information
   Activities & Events
   Melanoma Care Centers
   Slide Library
   Polling Results
   Patient Resources
   Contact Us
Log In


Managing adverse effects and improving patient compliance

CME Course Duration:

Start Date: December 2008
End Date: December 2009

Rosemary Giuliano, ARNP, MSN
Surgical Hospitalist
Department of Surgery
Morton Plant Mease Health Care
New Port Richey, FL

Featured Topic Information:
Please click here to view a webcast (registration required)
Please click here to view the slide library (registration required)
Please click here to listen to the audio (registration required)
Please click here to take the post test and evaluation (registration required)
Please click here if you have any comments or questions relating to this topic

Target Audience

This activity is directed toward surgical oncologists, general surgeons, oncology nurses, medical oncologists, dermatologists, and other healthcare professionals who treat or screen for melanoma.

Educational Objective

Identify drug-related adverse effects of various melanoma therapies

Summarize ways to manage adverse events and improve patient compliance

Faculty Disclosure Statement

Rosemary Giuliano has disclosed that she has served as a consultant for Topo Target and has participated on the speaker's bureau for Schering-Plough Corporation, Topo Target, and Genomic Health.

This CME program represents the views and opinions of the individual faculty for each case and does not constitute the opinion or endorsement of the editors, the advisory board, the publishing staff, Paradigm Medical Communications, the UPMC Center for Continuing Education in the Health Sciences, UPMC/University of Pittsburgh Medical Center or affiliates, or University of Pittsburgh School of Medicine.

Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions, including without limitation, FDA-approved uses, and any off-label uses.